Shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) have been assigned an average rating of “Hold” from the nine ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $11.80.
A number of brokerages recently issued reports on GNMK. Canaccord Genuity reissued a “buy” rating and set a $14.00 price target on shares of GenMark Diagnostics in a research report on Monday, October 30th. Needham & Company LLC reduced their price target on GenMark Diagnostics from $15.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Raymond James Financial reissued a “market perform” rating on shares of GenMark Diagnostics in a research report on Friday, November 3rd. Cowen reissued a “buy” rating and set a $10.00 price target on shares of GenMark Diagnostics in a research report on Friday, November 3rd. Finally, Zacks Investment Research downgraded GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th.
In related news, insider Hany Massarany sold 6,584 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $4.37, for a total transaction of $28,772.08. Following the sale, the insider now owns 357,190 shares of the company’s stock, valued at $1,560,920.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 21,836 shares of company stock worth $100,151 in the last three months. 7.50% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Fairpointe Capital LLC bought a new stake in GenMark Diagnostics during the fourth quarter worth $220,000. Teachers Advisors LLC lifted its stake in GenMark Diagnostics by 11.3% during the fourth quarter. Teachers Advisors LLC now owns 125,245 shares of the medical equipment provider’s stock worth $522,000 after purchasing an additional 12,713 shares during the last quarter. Two Sigma Investments LP lifted its stake in GenMark Diagnostics by 2,266.9% during the fourth quarter. Two Sigma Investments LP now owns 435,887 shares of the medical equipment provider’s stock worth $1,818,000 after purchasing an additional 417,471 shares during the last quarter. Two Sigma Advisers LP bought a new stake in GenMark Diagnostics during the fourth quarter worth $618,000. Finally, Needham Investment Management LLC lifted its stake in GenMark Diagnostics by 215.8% during the fourth quarter. Needham Investment Management LLC now owns 180,000 shares of the medical equipment provider’s stock worth $750,000 after purchasing an additional 123,000 shares during the last quarter.
GenMark Diagnostics (NASDAQ:GNMK) traded down $0.21 during trading on Friday, hitting $4.25. The stock had a trading volume of 333,136 shares, compared to its average volume of 479,234. GenMark Diagnostics has a 52 week low of $3.63 and a 52 week high of $13.67. The company has a quick ratio of 2.77, a current ratio of 2.97 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $240.55, a P/E ratio of -3.66 and a beta of 0.78.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/22/genmark-diagnostics-inc-gnmk-receives-average-rating-of-hold-from-analysts.html.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.